Trial Profile
A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 18 Nov 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 12 Jul 2019 According to NCT, inclusion criteria states Frontline patients who have not received prior systemic therapy and who have received =< 2 prior chemotherapy regimens.Since, info is not clear about progression, so second-line is not added in patient segement for now. Pls update further.